U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06875063) titled 'GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL' on March 08.
Brief Summary: To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Non-hodgkin Lymphoma,B Cell
Relapsed Non-Hodgkin Lymphoma
Refractory Lymphoma
Chimeric Antigen Receptor T-cell
Intervention:
DRUG: GB5005 CART
Included patients will receive GB5005 chimeric antigen receptor T-cell injection: A sterile syringe will be used to draw the assigned dose volume (calculated based on the pa...